Dr. William M. Mitchell
Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value
22 févr. 2016 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has announced that the Board of Directors has made several changes to its...
AIMLogo.jpg
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus
23 mars 2015 08h30 HE | AIM ImmunoTech Inc.
PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...